NCT06432166 - 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2028

Conditions

Alzheimer DiseaseMild Cognitive Impairment

Interventions

DRUG

2-hydroxybenzylamine acetate

2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks

OTHER

Placebo

Placebo taken three times per day for 16 weeks.

Trial Locations (1)

Center for Cognitive Medicine, Vanderbilt University Medical Center, Nashville